CAR-T PSCA Therapy: A New Hope for Castration-Resistant Prostate Cancer

Castration-resistant prostate cancer (mCRPC) presents a major challenge for healthcare professionals. Despite recent advances, treatment options for this deadly disease remain limited. CAR-T therapy, which involves modifying immune cells to specifically target and destroy cancer cells, has shown promise; however, its effectiveness against solid tumors has yet to be confirmed. This study explores the potential of CAR-T cells in treating mCRPC, specifically targeting the Prostate Stem Cell Antigen (PSCA). The primary objective is to assess the efficacy, safety, and potential effects of this approach in addressing the unmet therapeutic needs of patients with mCRPC.

CAR-T PSCA Therapy: Results And Initial Clinical Observations